Sanofi rolls out new Fluzone shots; Alexion's Soliris driving myasthenia gravis market growth;

> Sanofi's ($SNY) vaccines division shipped its first doses of Fluzone for the 2015-2016 influenza season in the U.S. Release

> Alexion's ($ALXN) rare disease drug Soliris could drive the value of the myasthenia gravis market to $550 million by 2024, GlobalData figures. Report

> Misuse of the anticoagulant warfarin is causing deaths and injuries in nursing homes, a ProPublica investigation found. Report

> Taiwan's pharma market is expected to rise to $8.4 billion by 2020, despite ongoing political tensions with China. Release

> Sarepta Therapeutics ($SRPT) is looking to buy another drug to treat Duchenne muscular dystrophy in its race with BioMarin Pharmaceutical ($BMRN) in the field. Report

And Finally... The FDA warned about the cardiovascular risks of NSAIDs last week, and experts now say they should be used sparingly. Report

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.